Bergen, 29 October 2025; Reference is made to the joint stock exchange
announcement made on 24 October 2025 by BerGenBio ASA and Oncoinvent ASA
("Oncoinvent") regarding key dates for completion of the combination of the two
companies through a statutory triangular merger (the "Merger"). Reference is
further made to the stock exchange announcement made on 28 October 2025
regarding the approval and publication of the prospectus (the "Prospectus")
prepared in connection with the Merger and the contemplated rights issue in the
combined company.
The last day of trading in the shares of Oncoinvent on Euronext Growth Oslo will
be today, 29 October 2025.
For further details on the timeline for completion of the Merger, please see the
announcements mentioned above and the Prospectus.
This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. One Phase 1 trial and one Phase 1/2a
trial have been completed and one randomized Phase 2 trial is currently ongoing
in the US, UK and Europe. Early clinical efficacy data are highly encouraging,
and no serious toxicity or safety concerns have been reported to date. The
Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art
manufacturing facility to produce drug products for clinical trials in Nydalen,
Oslo. Oncoinvent is listed on the Euronext Growth Oslo.
Forward-looking statement:
All statements other than statements of historical facts contained in this press
release are forward-looking statements and are not a representation that
Oncoinvent's plans, estimates, or expectations will be achieved. These forward
-looking statements represent Oncoinvent's expectations as of the date of this
press release, and Oncoinvent disclaims any obligation to update the forward
-looking statements. These forward-looking statements are subject to known and
unknown risks and uncertainties that may cause actual results to differ
materially, including with respect to whether the results of clinical or other
studies will support the use of our product offerings, the impact of results of
such studies, our expectations of the reliability, accuracy and performance of
our tests, or of the benefits of our tests and product offerings to patients,
providers and payers.